Loading
Loading
Research Overview
Mitochondria-derived peptide that translocates to the nucleus under metabolic stress and activates AMPK pathways; promotes glucose uptake in skeletal muscle, reduces insulin resistance, and regulates reactive oxygen species in preclinical models.
Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) is a mitochondrial-derived peptide that has been investigated in preclinical research for its potential role in cellular metabolism and energy regulation. Unlike many peptides encoded in the nuclear genome, MOTS-c originates from mitochondrial DNA, making it a unique subject of study in the context of intracellular signaling and metabolic adaptation. It consists of a short chain of amino acids and has been primarily examined in laboratory and animal-based models under controlled experimental conditions.
Across experimental settings, MOTS-c has been studied for its potential influence on metabolic pathways associated with glucose utilization, insulin sensitivity, and energy balance. Research has explored its interaction with key regulatory systems such as AMP-activated protein kinase (AMPK), as well as its involvement in pathways linked to mitochondrial function and cellular stress responses. These investigations often focus on how MOTS-c may contribute to adaptive signaling mechanisms that respond to changes in nutrient availability and metabolic demand.
In addition to metabolic regulation, MOTS-c has been evaluated for its potential role in maintaining cellular homeostasis during stress conditions in experimental models. Some findings suggest that it may be associated with pathways related to oxidative stress response, inflammation signaling, and age-related cellular processes, though these mechanisms remain under active investigation.
To support consistent research outcomes, MOTS-c has been synthesized and stabilized for laboratory use, enabling more controlled examination of its biological activity. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific research.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, mots-c peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
MOTS-c Peptide research is most relevant to protocols examining:
Mitochondrial biology and AMPK pathway research
Insulin resistance and glucose metabolism studies
Exercise-mimetic metabolic research
Longevity protocols investigating mitochondrial health preservation
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Mitochondria-derived peptide that translocates to the nucleus under metabolic stress and activates AMPK pathways; promotes glucose uptake in skeletal muscle, reduces insulin resistance, and regulates reactive oxygen species in preclinical models.
| Parameter | Value |
|---|---|
| Dose range | 5–10 mg/week |
| Schedule | 2–3× per week |
| Route | Subcutaneous |
| Half-life | ~Hours |
Expecting dramatic results from a single course
Fix: mitochondrial support is cumulative over months
Not combining with regular exercise
Fix: MOTS-c works synergistically with physical training
Storing improperly
Fix: requires cold-chain (refrigerated) storage
Dosing more frequently than 3× per week
Fix: higher frequency is not associated with better outcomes in research models
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
